Livedoid Vasculopathy Secondary to Protein C Deficiency:A Case Successfully Treated With Rivaroxaban  

作　　者：Nattanicha Chaisrimaneepan Tanongkiet Tienthavorn 

机构地区：[1]Institute of Dermatology,Ministry of Public Health,Bangkok 10400,Thailand [2]Division of Dermatosurgery,Institute of Dermatology,Department of Medical Services,Ministry of Public Health,Bangkok 10400,Thailand

出　　处：《International Journal of Dermatology and Venereology》2023年第3期175-177,共3页国际皮肤性病学杂志（英文）

摘　　要：Introduction:Livedoid vasculopathy is a chronic noninflammatory skin disease secondary to hypercoagulable states.No therapeutic guideline has yet been established for livedoid vasculopathy.We herein report a case of livedoid vasculopathy secondary to protein C deficiency that was successfully treated with rivaroxaban.Case presentation:A 31-year-old Thai woman who had been diagnosed with livedoid vasculopathy 10 years previously presented with a 2-month history of worsening leg ulcers and failure to respond to aspirin,colchicine,and pentoxifylline.Further investigations confirmed protein C deficiency.Rivaroxaban was initiated,and clinical improvement was achieved in 8 weeks.Discussion:When livedoid vasculopathy is confirmed by skin biopsy,additional investigations for hypercoagulable states should be performed to exclude secondary causes.Identification of the causes of livedoid vasculopathy can direct physicians to therapeutic options based on previously reported cases of successful treatment.Our patient,whose livedoid vasculopathy was caused by protein C deficiency,responded well to rivaroxaban.Conclusion:Protein C deficiency results in a hypercoagulable state,and affected patients can present with livedoid vasculopathy.The anticoagulant rivaroxaban has been beneficial in the treatment of livedoid vasculopathy.

关 键 词：livedoid vasculopathy protein C deficiency RIVAROXABAN HYPERCOAGULABILITY hypercoagulable state atrophie blanche 

分 类 号：R739.5[医药卫生—肿瘤]